Original articleEfficacy of Ranibizumab in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion: Results From the Sham-Controlled ROCC Study
Section snippets
Methods
This was a 6-month, prospective, multicenter, randomized, double-masked, sham-controlled, monitored study conducted at 4 sites in Norway. The aim of the study was to evaluate the efficacy and safety of intravitreal ranibizumab in patients with macular edema secondary to CRVO.
Patients with macular edema secondary to CRVO in 1 eye, who were previously untreated for this disease, were included in the study. Inclusion criteria included symptom duration ≤6 months, age ≥50 years, and a best-corrected
Baseline Characteristics
Of the 32 patients enrolled, 29 (16 male, 13 female) completed the study. One patient from the ranibizumab group developed retinal artery thrombosis and was withdrawn from the study shortly after the first injection.19 Two patients from the sham group were also withdrawn from the study, 1 for planned surgery because of cholecystitis and the other following a diagnosis of AMD, a protocol violation.
At baseline, the mean age was 72 years (52–88 years) and the mean duration of CRVO was 78 days
Discussion
In this 6-month study, intravitreal ranibizumab injections resulted in significant anatomic and visual improvements in patients with macular edema secondary to CRVO. The need for repeated monthly injections of intravitreal anti-VEGF therapy to maintain efficacy was confirmed in this study. Although this is time consuming and requires additional healthcare resources, anti-VEGF therapy may provide a treatment option for a disease for which an effective permanent therapy has not been established.
References (19)
- et al.
Intravitreal triamcinolone acetonide and intraocular pressure
Am J Ophthalmol
(2004) - et al.
Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion
Am J Ophthalmol
(2004) - et al.
Cataract progression after intravitreal triamcinolone injection
Am J Ophthalmol
(2005) Classification of central retinal vein occlusion
Ophthalmology
(1983)- et al.
Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate
Ophthalmology
(1996) - et al.
Early bevacizumab treatment of central retinal vein occlusion
Am J Ophthalmol
(2007) - et al.
A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema
Ophthalmology
(2006) - et al.
Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion
Am J Ophthalmol
(2009) - et al.
Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions
Ophthalmology
(2008)
Cited by (81)
Standardization of OCT Angiography Nomenclature in Retinal Vascular Diseases: First Survey Results
2021, Ophthalmology RetinaCitation Excerpt :The most used parameter in the literature has been the area of nonperfusion visible on fluorescein angiography, which was most frequently measured by the ONH area equivalents.55 An equivalent of ≥10 ONH areas was frequently used; however, other thresholds ranging from ≥5 to ≥30 were applied as well.56,57 There was consensus among the users that the differentiation of ischemic versus nonischemic RVO can be made on the basis of wide-field OCTA.
Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion
2018, Survey of OphthalmologyCitation Excerpt :For example, some have used a single test to define ischemic central retinal vein occlusion (iCRVO), such as fundus fluorescein angiography (FFA),1,2,18,36,37,43,66,85,127,136,152,177,209,219,225,239,241,247,263,294 electroretinography (ERG),2,129,154,161,167,189,198,311 or visual acuity (VA) of ≤20/200,22 whereas others have suggested the use of a combination of tests for this purpose.20,110,196,235 The most commonly used parameter to differentiate iRVO and non-iRVO has been the area of retinal capillary nonperfusion as determined by FFA.1,18,36,37,43,66,95,127,136,152,176,209,219,225,226,239,241,247,263,294 Most studies using FFA determined the total area of retinal capillary nonperfusion by measuring it and then dividing it by the optic disc area (DA) to calculate the area of retinal capillary nonperfusion in DAs.1,2
A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes
2023, Nephrology Dialysis TransplantationComparative Efficacy of Pharmacotherapy for Macular Edema Secondary to Retinal Vein Occlusion: A Network Meta-analysis
2021, Frontiers in PharmacologyEfficacy of different anti-VEGF drugs in the treatment of macular edema secondary to retinal vein occlusion: A systematic review
2021, Chinese Journal of Evidence-Based Medicine